Gemtesa’s manufacturer (Urovant Sciences) provides the Gemtesa Simple Savings Program. This is a financial assistance plan aimed at making Gemtesa (vibegron) — a treatment for overactive bladder in ...

NEEDHAM, Mass., Oct. 9, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development and ...

INDIANAPOLIS, Oct. 8, 2025 /PRNewswire/ -- Momentum Life Sciences announces the winners of the premier Patient Support Awards, known as The GoMentum Awards 2025. This inaugural program recognizes ...

Four years ago, Barbara LaCoste began seeing blurry spots in her central line of vision. During an eye exam at the John A. Moran Eye Center, the 78-year-old received a diagnosis that was all too ...

Non-receipt of targeted and immunotherapies in diverse patients with metastatic cancers. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium. This abstract does not include a ...

Associations of Financial Hardship and Health Status, Social Functioning, and Mental Health Among Cancer Survivors in the United States: Findings From a Nationally Representative Study Ulman ...

Laura Bobolts, PharmD, BCOP: It’s an exciting time in the landscape of patient-support services for patients with cancer in general, whether they’re patients with upper–GI [gastrointestinal] and ...

Nearly all of major AIDS drug companies have some form of patient assistance program to provide medications to patients in need who for whatever reason—lack of insurance coverage, lack of money to ...

Pharmaceutical companies are undergoing a profound transformation. No longer confined to merely developing treatments, companies are assuming a partnership role to collaborate with healthcare ...

Anna Sutton was shocked when she received a letter from her husband’s job-based health plan stating that Humira, an expensive drug used to treat her daughter’s juvenile arthritis, was now on a long ...

The company raised its 2025 revenue guidance to a range of $80.5 million to $81.5 million, reflecting year-over-year growth of 38.7% at the midpoint. Plasma is estimated to make up approximately 57% ...

Greater transparency and independent evaluation are needed to understand the impact of the patient support programs that pharmaceutical companies offer for many expensive drugs, according to ...